A comment on futility monitoring

被引:37
作者
Freidlin, B [1 ]
Kom, EL [1 ]
机构
[1] NCI, Biometr Res Branch, Bethesda, MD 20892 USA
来源
CONTROLLED CLINICAL TRIALS | 2002年 / 23卷 / 04期
关键词
conditional power; clinical trial; futility; interim monitoring; monitoring guidelines; stochastic curtailment;
D O I
10.1016/S0197-2456(02)00218-0
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Futility monitoring of randomized clinical trials is becoming widely used. In this paper we discuss several concerns associated with aggressive monitoring for lack of activity in studies comparing experimental and control treatment arms: (1) stopping for futility when the experimental arm is doing better than the control arm, (2) conditional power not being low at the time of stopping, (3) potential loss of power to detect clinically interesting differences that are smaller than the design alternative, and (4) sensitivity of the power to the departure from the proportional hazards assumption. Our investigation suggests that aggressive futility rules do not generally reduce power (relative to less aggressive rules) under incorrect design assumptions such as overstatement of the target treatment effect or mild violations of the proportional hazards assumption. On the other hand, aggressive monitoring rules may result in an early termination for futility when the experimental arm is doing better than the control arm (in some cases nontrivially better, especially when trials are designed for unrealistically large effects). Thus, aggressive monitoring rules may fail to provide sufficiently convincing evidence to influence clinical practice or to establish a standard of treatment. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:355 / 366
页数:12
相关论文
共 30 条
[1]   CLINICAL-TRIAL DATA AND SAFETY MONITORING BOARDS - THE SEARCH FOR A CONSTITUTION [J].
ARMSTRONG, PW ;
FURBERG, CD .
CIRCULATION, 1995, 91 (03) :901-904
[2]  
Betensky RA, 1997, STAT MED, V16, P465, DOI 10.1002/(SICI)1097-0258(19970228)16:4<465::AID-SIM384>3.0.CO
[3]  
2-R
[4]  
DEMETS DL, 1982, BIOMETRIKA, V69, P661
[5]  
DEMETS DL, 1980, BIOMETRIKA, V67, P651
[6]   The agonising negative trend in monitoring of clinical trials [J].
DeMets, DL ;
Pocock, SJ ;
Julian, DG .
LANCET, 1999, 354 (9194) :1983-1988
[7]  
ELLENBERG SS, 1985, CANCER TREAT REP, V69, P1147
[8]   SYMMETRIC GROUP SEQUENTIAL TEST DESIGNS [J].
EMERSON, SS ;
FLEMING, TR .
BIOMETRICS, 1989, 45 (03) :905-923
[9]   DESIGNS FOR GROUP SEQUENTIAL-TESTS [J].
FLEMING, TR ;
HARRINGTON, DP ;
OBRIEN, PC .
CONTROLLED CLINICAL TRIALS, 1984, 5 (04) :348-361
[10]   Data monitoring committees and interim monitoring guidelines [J].
Freidlin, B ;
Korn, EL ;
George, SL .
CONTROLLED CLINICAL TRIALS, 1999, 20 (05) :395-407